Meet the woman challenging South Korean norms by driving value through patents
“IP is everything for the innovation of science,” Sue Soheui Choe, founder and IP head of biotech start-up Atheon Bio, tells IAM
“IP is everything for the innovation of science,” Sue Soheui Choe, founder and IP head of biotech start-up Atheon Bio, tells IAM
IAM has launched a specialist trade secrets hub providing practical and timely guidance for practitioners trying to navigate this fast-moving space
AST’s most recent patent deals report measures an uptick in activity in the US patent secondary market
07 March 2024
Trade secrets are an effective means to complement and supplement patent portfolios, because they can be an effective way to protect gaps that patents cannot fill. However, the pace at which tech is being employed in Sweden has hugely increased the risk of trade secrets being breached.
07 March 2024
A Delhi High Court division bench has outlined that patent protection deriving from product-by-process claims will extend to the product itself, provided it is novel and inventive. This judgment provides much-needed clarity on an issue that was sorely lacking elucidation in Indian jurisprudence.
06 March 2024
The company will be looking to make up for the terrible reversal of fortunes it has suffered in long-running spat with Sanofi and Regeneron
29 February 2024
The Bolar exemption, which is outlined in the Law No 6769, is resulting in a significant number of court filings, seeking determination of non-infringement of pharma patents by licence applications for generic products. Due to this rule, generics companies are hoping to be able to launch their generic products as soon as their patents expire by obtaining a non-infringement declaration during the licensing period before the Turkish Ministry of Health.
29 February 2024
First appellate PI decision comes as first instance judges largely opt to rule against preliminary sales bans
27 February 2024
Newly released report throws light on which life sciences companies have the most dynamic IP portfolios
22 February 2024
IAM talked with Petro Terblanche, CEO of Afrigen Biologics, about the WHO vaccine hub and its IP strategy
21 February 2024
Reversal in favour of Vifor is a boon for innovators
20 February 2024
Reversal has major implications for future disputes involving rare disease treatments
12 February 2024
Unlock unlimited access to all IAM content